Table 1 Characteristics of patients having benefited of 123I-FP-CIT SPECT.
From: Relevance of 123I-FP-CIT SPECT prescriptions for the diagnosis of parkinsonian syndromes
Total n = 723 | Inappropriate indication (a) n = 271 (37.5%) | Uncertain indication (b) n = 178 (24.6%) | Relevant indication (c) n = 274 (37.9%) | p ‡ | |
|---|---|---|---|---|---|
Sex (Female) | 329 (45.5%) | 120 (44.3%) | 80 (44.9%) | 129 (47.1%) | 0.800 |
Age at exam (years) | 69.8 ± 11.4 | 70.9 ± 11.0 | 69.3 ± 12.4 | 69.1 ± 11.0 | 0.134 |
Disease duration (years) | |||||
Available data, n (%) | 290 (40.1%) | 119 (43.9%) | 56 (31.5%) | 115 (42.0%) | |
Mean ± standard deviation | 3.8 ± 5.7 | 3.3 ± 4.5 | 2.4 ± 2.5 c | 4.9 ± 7.5 b | 0.011* |
Medical history | |||||
Available data, n (%) | 506 (70.0%) | 190 (70.1%) | 111 (62.4%) | 205 (74.8%) | |
Cardiovascular and pulmonary | 328 (67.2%) | 129 (69.0%) | 71 (66.4%) | 128 (66.0%) | 0.820 |
Endocrinological | 175 (35.7%) | 70 (37.2%) | 36 (33.6%) | 69 (35.4%) | 0.836 |
Orthopedic and rheumatological | 157 (32.0%) | 64 (34.2%) | 38 (34.9%) | 55 (28.3%) | 0.356 |
Neurological | 136 (27.6%) | 58 (30.7%) | 20 (18.7%) | 58 (29.4%) | 0.064 |
Psychiatric | 177 (35.6%) | 52 (27.8%) c | 33 (30.3%) c | 92 (45.8%) a, b | 0.001* |
Treatments | |||||
Available data, n (%) | 494 (68.3%) | 182 (67.2%) | 108 (60.7%) | 204 (74.4%) | |
Neuroleptics | 99 (20.3%) | 18 (9.9%) c | 13 (12.4%) c | 68 (33.8%) a, b | < 0.001* |
Dopaminergic therapy | 62 (12.9%) | 39 (21.4%) b, c | 7 (6.6%) a | 16 (8.3%) a | < 0.001* |
Tremorigenic drugs | 326 (68.1%) | 115 (63.5%) | 70 (65.4%) | 141 (73.8%) | 0.078 |
Brain imaging results (MRI or CT-scan) | |||||
Available data, n (%) | 381 (52.7%) | 151 (55.7%) | 76 (42.7%) | 154 (56.2%) | |
Normal | 65 (17.1%) | 23 (15.2%) | 16 (21.0%) | 26 (16.9%) | 0.545 |
Leukopathy | 232 (61.2%) | 94 (62.7%) | 45 (59.2%) | 93 (60.8%) | 0.886 |
Stroke sequelae | 93 (24.5%) | 41 (27.3%) | 14 (18.4%) | 38 (24.8%) | 0.331 |
Brainstem lesions | 18 (4.7%) | 7 (4.6%) | 3 (3.9%) | 8 (5.2%) | 1.000 |
Cerebellar lesions | 31 (8.2%) | 8 (5.3%) | 5 (6.6%) | 18 (11.7%) | 0.134 |
Atrophy | 225 (59.2%) | 101 (67.3%) b | 38 (50.0%) a | 86 (55.8%) | 0.023* |
NPH | 4 (0.6%) | 0 | 0 | 4 (1.5%) | 0.043* |
123I-FP-CIT SPECT conclusion | b,c | a | a | < 0.001* | |
Normal | 236 (32.6%) | 54 (19.9%) | 62 (34.8%) | 120 (43.8%) | |
Dopaminergic denervation | |||||
Bilateral symmetric | 99 (13.7%) | 50 (18.4%) | 19 (10.7%) | 30 (11.0%) | |
Bilateral asymmetric | 236 (32.6%) | 114 (42.1%) | 53 (29.8%) | 69 (25.2%) | |
Unilateral | 114 (15.8%) | 46 (17.0%) | 28 (15.7%) | 40 (14.6%) | |
Doubtful | 38 (5.3%) | 7 (2.6%) | 16 (9.0%) | 15 (5.5%) | |
Final diagnoses | |||||
Available data, n (%) | 406 (56.1%) | 161 (59.4%) | 81 (45.5%) | 164 (59.8%) | |
Parkinson’s disease | 124 (30.7%) | 56 (35.0%) | 25 (30.9%) | 43 (26.4%) | 0.244 |
Atypical PS | 92 (22.8%) | 42 (26.2%) | 22 (27.2%) | 28 (17.2%) | 0.073 |
Essential tremor | 28 (6.9%) | 2 (1.2%) b, c | 8 (9.9%) a | 18 (11.1%) a | 0.001* |
Non-Parkinsonian dementia | 28 (6.9%) | 9 (5.6%) | 7 (8.6%) | 12 (7.4%) | 0.618 |
Iatrogenic PS | 44 (10.9%) | 3 (1.9%) c | 3 (3.7%) c | 38 (23.3%) a, b | < 0.001* |
Vascular PS | 22 (5.4%) | 9 (5.6%) | 4 (4.9%) | 9 (5.5%) | 1.000 |
Functional PS | 5 (1.2%) | 1 (0.6%) | 1 (1.2%) | 3 (1.8%) | 0.840 |
NPH-related PS | 12 (3.0%) | 7 (4.3%) | 0 (0.0%) | 5 (3.0%) | 0.128 |
Pyramidal syndrome | 6 (1.5%) | 5 (3.1%) | 0 (0.0%) | 1 (0.6%) | 0.123 |
Orthopedic or rheumatological disorder | 4 (1.0%) | 3 (1.9%) | 1 (1.2%) | 0 (0.0%) | 0.194 |
Other | 14 (3.5%) | 5 (3.1%) | 4 (4.9%) | 5 (3.1%) | 0.728 |
Unlabelled | 57 (14.1%) | 32 (20.0%) c | 10 (12.3%) | 15 (9.2%) a | 0.020* |
